NeoGenomics Launches PanTracer Pro to Accelerate Solid Tumor Therapy Decisions
Event summary
- NeoGenomics launched PanTracer Pro on February 12, 2026, a new diagnostic tool for advanced-stage solid tumors.
- PanTracer Pro integrates comprehensive genomic profiling with tumor-specific ancillary testing, reducing turnaround time to 8–10 days.
- The tool aims to streamline molecular testing workflows and reduce diagnostic uncertainty for clinicians.
- PanTracer Pro can automatically reflex to PanTracer LBx liquid biopsy assay if tissue samples are insufficient.
The big picture
NeoGenomics' PanTracer Pro addresses the growing complexity in precision oncology, where clinicians face mounting pressure to initiate treatment quickly. The tool's ability to deliver comprehensive genomic insights through a single coordinated order could set a new standard for diagnostic efficiency, potentially reshaping how solid tumor therapies are selected. The launch underscores the industry's shift toward integrated diagnostic solutions that reduce delays and improve treatment outcomes.
What we're watching
- Adoption Pace
- How quickly clinicians will integrate PanTracer Pro into existing workflows and its impact on treatment timelines.
- Competitive Response
- Whether competitors will introduce similar comprehensive diagnostic tools, potentially pressuring NeoGenomics' market position.
- Regulatory Scrutiny
- The extent to which regulatory bodies will review the tool's claims, particularly around biomarker reliability and treatment efficacy.
Related topics